Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 2,583,200 | 2,566,500 | 2,671,200 | 2,802,200 | 2,922,545 |
| Cost of Goods | 1,243,300 | 1,187,600 | 1,244,300 | 1,234,900 | 1,284,449 |
| Gross Profit | 1,339,900 | 1,378,900 | 1,426,900 | 1,567,300 | 1,638,096 |
| Operating Expenses | 1,293,000 | 1,110,500 | 1,089,400 | 1,085,600 | 1,138,209 |
| Operating Income | 47,200 | 269,000 | 337,800 | 482,600 | 500,336 |
| Interest Expense | 49,000 | 48,900 | 49,400 | 38,100 | 1,551 |
| Other Income | 997,300 | -2,562,600 | -1,138,500 | -5,148,700 | 4,950,270 |
| Pre-tax Income | 995,500 | -2,342,500 | -850,100 | -4,704,200 | 5,449,055 |
| Income Tax | 235,600 | -498,300 | -212,800 | -1,076,700 | 1,194,798 |
| Net Income Continuous | 759,900 | -1,844,200 | -637,300 | -3,627,500 | 4,254,257 |
| Net Income | $759,900 | $-1,844,200 | $-637,300 | $-3,627,500 | $4,254,257 |
| EPS Basic Total Ops | 27.87 | -65.36 | -21.82 | -121.79 | 142.61 |
| EPS Basic Continuous Ops | 27.87 | -65.36 | -21.82 | -121.79 | 142.61 |
| EPS Diluted Total Ops | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 |
| EPS Diluted Continuous Ops | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 |
| EPS Diluted Before Non-Recurring Items | 9.92 | 10.31 | 11.78 | 14.42 | 15.66 |
| EBITDA(a) | $47,200 | $269,000 | $337,800 | $482,600 | $500,336 |